Friday 02 May 2025
Internal Reference Number: FOI_8510
Date Request Received: 10/03/2025 00:00:00
Date Request Replied To: 20/03/2025 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq) - < 5 patients • Durvalumab (Imfinzi) - 0 • Nivolumab (Opdivo) - 0 • Pembrolizumab (Keytruda) - <5 patients • Chemotherapy - 8 patients • Radiotherapy - not given at this Trust • Chemotherapy AND Radiotherapy - not given at this Trust • Osimertinib - <5 patients | |
| Question Number 2: How many patients were treated in the past 3 months for gastric cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only • Zolbetuximab (Vyloy) | |
| Answer To Question 2: CAPOX (Capecitabine with Oxaliplatin) - 0 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0 • Lonsurf (Trifluridine - tipiracil) - 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - <5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy - <5 patients • Palliative care only • Zolbetuximab (Vyloy) - 0 | |
| Question Number 3: How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Zolbetuximab (Vyloy) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: CAPOX (Capecitabine with Oxaliplatin) - < 5 patients • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0 • Lonsurf (Trifluridine - tipiracil) - 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - , 5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - < 5 patients • Zolbetuximab (Vyloy) - 0 • Any other systemic anti-cancer therapy - 7 patients • Palliative care only | |
| Question Number 4: How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? | |
| Answer To Question 4: How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? - 15 patients | |
| Question Number 5: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? | |
| Answer To Question 5: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? - Not treated at this Trust. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
